Cencora

(New York Stock Exchange)
Back to all articles
Bullish +65

Cencora, Inc. (COR) Expands Into Retina Services Business in $1.1B Deal

AI-generated analysis

πŸ“ˆ Cencora (COR) acquires EyeSouth's partner's retina business for a total deal value of $1.1 billion.

πŸ’° The acquisition is financed using the company's existing credit facilities and available cash reserves.

πŸ“Š Analysts UBS and Evercore ISI maintain Buy/Outperform ratings with price targets of $410 and $420.

πŸš€ The deal is projected to be accretive to adjusted earnings per share within the first 12 months post-close.

πŸ’Ό The transaction strengthens Cencora's retina platform, which generated $600M revenue and $75M EBITDA in 2022.

🀝 The acquisition creates synergies with the existing RCA business by integrating all providers onto a single platform.

πŸ₯ Cencora operates as a primary wholesale distributor connecting drug manufacturers with hospitals, pharmacies, and clinics.

Bullish Signals
  • The $1.1 billion acquisition of EyeSouth's retina business is expected to be accretive to adjusted earnings per share within the first 12 months following the close.
  • Major investment banks UBS and Evercore ISI have reiterated Buy/Outperform ratings with price targets of $410 and $420, signaling strong institutional confidence in the deal's value creation.
  • The acquisition expands Cencora into a high-growth specialty business segment, diversifying its revenue streams beyond traditional wholesale distribution.
  • The deal strengthens an existing retina platform that already generated $600 million in revenue and $75 million in EBITDA in 2022, indicating immediate operational scale.
  • Integration of all providers onto a unified platform with the existing RCA business is expected to generate significant cost synergies and operational efficiencies.
Full Analysis
Cencora, Inc. (NYSE: COR) announced a strategic acquisition of EyeSouth's partner's retina business for $1.1 billion, marking a significant expansion into the specialty pharmaceutical services sector. The deal is financed through existing credit facilities and cash reserves, with analysts from UBS and Evercore ISI reiterating their Buy/Outperform ratings and raising price targets to $410 and $420 respectively. The acquisition is expected to be accretive to adjusted earnings per share within the first 12 months following the transaction's close. This move strengthens Cencora's existing retina platform, which generated $600 million in revenue and $75 million in EBITDA in 2022, while creating synergies with its current RCA business by integrating all providers onto a unified platform. Cencora operates as a leading global pharmaceutical solutions organization, acting as a primary wholesale distributor connecting drug manufacturers with healthcare providers. The company distributes brand-name, generic, and specialty drugs to hospitals, pharmacies, and clinics while providing logistics, supply chain optimization, and commercialization services for biopharma companies.